Novo Nordisk A/S (NYSE:NVO) Short Interest Down 14.9% in February

Novo Nordisk A/S (NYSE:NVO) was the recipient of a large decline in short interest in February. As of February 13th, there was short interest totaling 26,973,270 shares, a decline of 14.9% from the January 29th total of 31,693,294 shares. Currently, 0.6% of the company’s stock are sold short. Based on an average daily volume of 30,479,797 shares, the short-interest ratio is currently 0.9 days. Based on an average daily volume of 30,479,797 shares, the short-interest ratio is currently 0.9 days. Currently, 0.6% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Weiss Ratings raised Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, February 5th. TD Cowen reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 3rd. Nordea Equity Research downgraded shares of Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. Morgan Stanley upgraded shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target on the stock in a report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Five investment analysts have rated the stock with a Buy rating, seventeen have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $53.93.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Quotient Wealth Partners LLC boosted its holdings in shares of Novo Nordisk A/S by 2.0% in the fourth quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock worth $463,000 after acquiring an additional 177 shares during the period. Certuity LLC boosted its stake in Novo Nordisk A/S by 3.6% in the 4th quarter. Certuity LLC now owns 5,052 shares of the company’s stock worth $257,000 after purchasing an additional 177 shares during the period. Beacon Financial Group grew its holdings in Novo Nordisk A/S by 4.3% during the 3rd quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock valued at $239,000 after buying an additional 178 shares in the last quarter. Oakworth Capital Inc. grew its holdings in Novo Nordisk A/S by 41.6% during the 4th quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock valued at $31,000 after buying an additional 182 shares in the last quarter. Finally, True North Advisors LLC increased its position in shares of Novo Nordisk A/S by 3.9% during the fourth quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock valued at $270,000 after buying an additional 199 shares during the period. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO traded up $1.84 during mid-day trading on Wednesday, reaching $38.50. The company had a trading volume of 23,051,653 shares, compared to its average volume of 26,902,344. Novo Nordisk A/S has a one year low of $35.85 and a one year high of $91.90. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The company’s 50-day moving average price is $52.24 and its 200-day moving average price is $52.68. The firm has a market cap of $171.90 billion, a price-to-earnings ratio of 11.10 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be issued a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio is 23.63%.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Morgan Stanley upgraded NVO to Equal-weight, saying the recent sell-off better prices mid‑term risks and setting a $40 price target — this reduced perceived downside and likely helped buying interest. Morgan Stanley upgrades Novo Nordisk, says risks better priced after sell-off
• Positive Sentiment: Investors reacted to FDA moves against telehealth GLP‑1 advertisers as potentially removing low‑quality/rogue competition and stabilizing branded channel economics for incumbents like Novo. Novo Nordisk (NVO) Stock Jumps 3% as FDA Cracks Down on Telehealth GLP-1 Advertisers
• Positive Sentiment: Company is investing heavily in production capacity (Ireland facility upgrades and a Monksland expansion) to secure supply for Wegovy and oral formulations — positive for long‑term market defense. Novo Nordisk Announces $372.5M Expansion in Monksland, Athlone, Ireland
• Neutral Sentiment: Market debate on valuation and whether current pricing reflects too much pessimism continues; some pieces argue downside is priced while others flag remaining execution/competitive risks. Is Novo Nordisk (NYSE:NVO) Now Pricing In Too Much Pessimism After Share Price Slump
• Neutral Sentiment: Roche and other rivals are explicitly targeting the obesity market — a longer‑term competitive factor investors are watching but not an immediate earnings shock. Roche targets double-digit market share in weight loss, aims to catch up with Novo
• Negative Sentiment: The FDA issued a second warning ordering Novo to stop a consumer Ozempic ad for being misleading — immediate regulatory/marketing headwind and reputational risk. US FDA warns Novo for second time about misleading Ozempic advertising
• Negative Sentiment: Pomerantz has opened an investor investigation into Novo — potential litigation risk that can weigh on sentiment if it escalates. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S – NVO
• Negative Sentiment: Planned halving of Wegovy’s US list price in 2027 signals pricing pressure and margin risk for the obesity franchise (volume vs. price trade‑off). Novo Nordisk to halve US list price of Wegovy in 2027
• Negative Sentiment: The American Hospital Association urged HRSA to stop Novo’s new claims‑data submission policy affecting 340B hospitals, adding regulatory and stakeholder friction. AHA urges HRSA to stop Novo Nordisk’s new claims-data submission policy on 340B hospitals from going into effect
• Negative Sentiment: Generic/biosimilar Ozempic competition is progressing (Canada generic anticipated), a potential revenue headwind in affected markets. Aspen expects Canada nod for generic targeting Novo’s Ozempic by September

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.